医药健康与生命科学
特发性血小板减少性紫癜（ITP）治疗药物市场（2026—2031）
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
特发性血小板减少性紫癜（ITP）治疗药物市场规模预计由2026年的7.342亿美元增至2031年的9.7836亿美元，预测期复合年增长率为5.91%。北美是当前最大市场，亚太地区增长最快。
浏览7
更新时间2026-09-03
内容类型市场研究报告
市场研究正文
规模、增长、细分、驱动因素与关键问题
内容模板：完整版
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
特发性血小板减少性紫癜（ITP）治疗药物市场规模预计由2026年的7.342亿美元增至2031年的9.7836亿美元，预测期复合年增长率为5.91%。北美是当前最大市场，亚太地区增长最快。
市场走势
市场规模变化
预测期复合增长率 CAGR5.91%机构预测 · 2031
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.91% | 机构预测 |
| 市场规模 | 2026 | USD 734.2 million | 机构预测 |
| 市场规模 | 2031 | USD 978.36 million | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_duration | chronic ITP | 2025 | 47.600% |
| distribution_channel | hospital pharmacies | 2025 | 52.300% |
| geography | North America | 2025 | 43.100% |
| patient_age_group | adults | 2025 | 72.400% |
| route_of_administration | oral therapies | 2025 | 51.800% |
| treatment_type | thrombopoietin receptor agonists | 2025 | 38.900% |
关键结论
- disease_duration 维度中，chronic ITP 在 2025 年的公开份额为 47.6%。
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 52.3%。
- geography 维度中，North America 在 2025 年的公开份额为 43.1%。
- patient_age_group 维度中，adults 在 2025 年的公开份额为 72.4%。
- route_of_administration 维度中，oral therapies 在 2025 年的公开份额为 51.8%。
- treatment_type 维度中，thrombopoietin receptor agonists 在 2025 年的公开份额为 38.9%。
主要参与者
- Novartis AG
- Amgen Inc.
- Grifols, S.A.
- Swedish Orphan Biovitrum AB (Sobi)
- CSL Limited
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Increasing Diagnosis of Persistent and Chronic ITP | +1.500% | Global | Medium term (2-4 years) |
| Shift Toward Targeted Steroid-Sparing Therapies | +1.200% | North America and Europe | Medium term (2-4 years) |
| Expansion of Pediatric Treatment Eligibility | +0.500% | North America and Europe | Short term (≤ 2 years) |
| Growth of Outpatient and Home-Based Oral Treatment | +0.700% | Global | Medium term (2-4 years) |
| FcRn, BTK, SYK, and B-Cell Pathway Innovation | +1.300% | North America, EU, APAC core, and spillover to MEA | Long term (≥ 4 years) |
| Orphan-Disease Incentives and Specialty-Hematology Investment | +0.600% | North America, EU, and Japan | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High Annual Cost of Novel Therapies | -0.800% | Global, most acute in uninsured and public-payer settings | Medium term (2-4 years) |
| Variable Reimbursement and Prior Authorization | -0.600% | North America and EU | Medium term (2-4 years) |
| Long-Term Safety and Thrombosis Monitoring Burden | -0.400% | Global | Long term (≥ 4 years) |
| Limited Durable Remission and Treatment Sequencing Uncertainty | -0.400% | Global | Long term (≥ 4 years) |
报告关注的关键问题
What is driving demand for ITP therapeutics?
Diagnosis of persistent and chronic disease, steroid-sparing treatment, and new targeted therapies support demand.
What is the projected growth rate for ITP therapeutics through 2031?
The sector is forecast to grow at a 5.90% CAGR from 2026 to 2031.
Which treatment type leads ITP therapy revenue?
Thrombopoietin receptor agonists led with 38.90% revenue share in 2025.
Which patient group is growing fastest in ITP treatment?
The geriatric group is forecast to expand at a 7.60% CAGR through 2031.
Why are oral ITP therapies gaining use?
Oral options reduce clinic visits and support home-based long-term platelet management.
Which region has the fastest growth outlook for ITP therapeutics?
Asia-Pacific is forecast to grow at a 9.30% CAGR through 2031.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
Vieter 校准：机构预测不等于实际成交、订单、交付或出货。跨报告比较需要同时核对市场边界、基准年、币种及是否包含软件服务。本站不提供报告原文或全文译文。
查看来源：Mordor Intelligence
查看来源：Mordor Intelligence